Q3 Earnings Forecast for Climb Bio Issued By Leerink Partnrs

Key Points

• Leerink Partnrs has raised its Q3 2025 earnings per share (EPS) estimate for Climb Bio to ($0.16), indicating an improvement from their earlier forecast of ($0.19).
• Climb Bio's stock currently has a consensus rating of "Buy" with an average price target of $9.00, supported by reports from multiple analysts.
• The company recently reported earnings of ($0.13) per share, surpassing expectations and demonstrating positive momentum as shares increased by 5.5% in trading.

Climb Bio, Inc. (NASDAQ:CLYM - Free Report) - Leerink Partnrs lifted their Q3 2025 earnings per share estimates for shares of Climb Bio in a report issued on Tuesday, August 12th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings per share of ($0.16) for the quarter, up from their previous forecast of ($0.19). The consensus estimate for Climb Bio's current full-year earnings is ($1.57) per share. Leerink Partnrs also issued estimates for Climb Bio's Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.78) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at ($1.02) EPS, FY2028 earnings at ($1.57) EPS and FY2029 earnings at ($2.54) EPS.

Climb Bio (NASDAQ:CLYM - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.06.

A number of other brokerages have also recently commented on CLYM. BTIG Research initiated coverage on Climb Bio in a research report on Thursday, May 22nd. They set a "buy" rating for the company. Oppenheimer initiated coverage on Climb Bio in a research report on Friday, June 6th. They set an "outperform" rating and a $10.00 price target for the company. Baird R W raised Climb Bio to a "strong-buy" rating in a research report on Friday, August 15th. Finally, Robert W. Baird initiated coverage on Climb Bio in a research report on Friday, August 15th. They set an "outperform" rating and a $9.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating and four have given a Buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $9.00.

Climb Bio Price Performance

NASDAQ CLYM traded up $0.04 during midday trading on Friday, hitting $2.06. 225,471 shares of the company traded hands, compared to its average volume of 339,984. The company has a market cap of $139.59 million, a PE ratio of -2.94 and a beta of -0.11. The company's 50-day simple moving average is $1.44 and its 200-day simple moving average is $1.37. Climb Bio has a 52 week low of $1.05 and a 52 week high of $8.79.

Hedge Funds Weigh In On Climb Bio

Several institutional investors and hedge funds have recently modified their holdings of the business. Peapod Lane Capital LLC acquired a new position in Climb Bio in the first quarter valued at approximately $676,000. TD Asset Management Inc acquired a new position in Climb Bio in the first quarter valued at approximately $109,000. Bank of New York Mellon Corp acquired a new position in Climb Bio in the first quarter valued at approximately $79,000. XTX Topco Ltd acquired a new position in Climb Bio in the first quarter valued at approximately $34,000. Finally, Persistent Asset Partners Ltd acquired a new position in Climb Bio in the first quarter valued at approximately $178,000. Hedge funds and other institutional investors own 69.76% of the company's stock.

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.